2 recruiting, 1 completed. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow TearSolutions, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects With Neurotrophic Keratitis Lacripep, Vehicle Ophthalmic Solution - Neurotrophic Keratitis | Phase 2 | Recruiting | TearSolutions, Inc. | 54 | 2026-02-19 | 2026-09-25 |
| Lacripep for Corneal Wound Healing Study 0.00025% Lacripep ophthalmic solution and Placebo - Corneal Epithelial Wound Healing | Phase 2 | Recruiting | Henry M. Jackson Foundation for the Advancement of Military Medicine | 88 | 2025-05-23 | 2026-09-03 |
| Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome 0.005% Lacripep, 0.01% Lacripep, Placebo - Primary Sjögren Syndrome, Dry Eye | Phase 1 / Phase 2 | Completed | TearSolutions, Inc. | 204 | 2017-06-30 | 2020-01-22 |
Corneal Diseases (1) · Dry Eye Syndromes (1) · Sjogren's Syndrome (1)
United States (3)
Marc Odrich, MD (2) · Benjamin G Kuhar, OD (1)